Cargando…

A Phase I study of pevonedistat plus capecitabine plus oxaliplatin in patients with advanced gastric cancer refractory to platinum (NCCH-1811)

Based on synergistic anti-tumor effects between blockades of NEDD8 activating enzyme and a platinum in preclinical studies, this Phase I study is designed to investigate the safety and tolerability of pevonedistat in combination with capecitabine plus oxaliplatin as third-line or later treatment in...

Descripción completa

Detalles Bibliográficos
Autores principales:	Shoji, Hirokazu, Takahari, Daisuke, Hara, Hiroki, Nagashima, Kengo, Adachi, Jun, Boku, Narikazu
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Future Science Ltd 2021
Materias:	Clinical Trial Protocol
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8256327/ https://www.ncbi.nlm.nih.gov/pubmed/34258028 http://dx.doi.org/10.2144/fsoa-2021-0023

Ejemplares similares

Phase I/II Study of Capecitabine Plus Oxaliplatin (XELOX) Plus Bevacizumab As First-line Therapy in Japanese Patients with Metastatic Colorectal Cancer
por: Doi, Toshihiko, et al.
Publicado: (2010)

Hepatectomy Followed by Adjuvant Chemotherapy with 3‐Month Capecitabine Plus Oxaliplatin for Colorectal Cancer Liver Metastases
por: Satake, Hironaga, et al.
Publicado: (2021)

Phase II study of lenvatinib for metastatic colorectal cancer refractory to standard chemotherapy: the LEMON study (NCCH1503)
por: Iwasa, Satoru, et al.
Publicado: (2020)

Oxaliplatin plus Capecitabine in the Perioperative Treatment of Locally Advanced Gastric Adenocarcinoma in Combination with D2 Gastrectomy: NEO‐CLASSIC Study
por: Yu, Yiyi, et al.
Publicado: (2019)

Pevonedistat plus azacitidine vs azacitidine alone in higher-risk MDS/chronic myelomonocytic leukemia or low-blast-percentage AML
por: Adès, Lionel, et al.
Publicado: (2022)

Perioperative TAS-118 plus oxaliplatin in patients with locally advanced gastric cancer: APOLLO-11 study
por: Takahari, Daisuke, et al.
Publicado: (2023)

Capecitabine Plus Oxaliplatin Combination Therapy for Basal Cell Carcinoma
por: Rhee, Jiyoung, et al.
Publicado: (2019)

Three-Year Outcomes of a Phase II Study of Perioperative Capecitabine Plus Oxaliplatin Therapy for Clinical SS/SE N1-3 M0 Gastric Cancer (OGSG 1601)
por: Matsuyama, Jin, et al.
Publicado: (2022)

Study protocol of a single-arm phase 2 study evaluating the preventive effect of topical hydrocortisone for capecitabine-induced hand-foot syndrome in colorectal cancer patients receiving adjuvant chemotherapy with capecitabine plus oxaliplatin (T-CRACC study)
por: Iimura, Yohei, et al.
Publicado: (2022)

Cost-Effectiveness Analysis of Capecitabine Plus Oxaliplatin Versus Gemcitabine Plus Oxaliplatin as First-Line Therapy for Advanced Biliary Tract Cancers
por: Chen, Ruijia, et al.
Publicado: (2022)

Retrospective study of preoperative chemoradiotherapy with capecitabine versus capecitabine plus oxaliplatin for locally advanced rectal cancer
por: Yang, Xiao-Hui, et al.
Publicado: (2020)

Toxicity associated with capecitabine plus oxaliplatin in colorectal cancer before and after an institutional policy of capecitabine dose reduction
por: Baird, R, et al.
Publicado: (2011)

Cost-effectiveness analysis of capecitabine monotherapy versus capecitabine plus oxaliplatin in elderly patients with advanced gastric cancer
por: Peng, Jingyuan, et al.
Publicado: (2018)

A Phase II Study of Sequential Capecitabine Plus Oxaliplatin Followed by Docetaxel Plus Capecitabine in Patients With Unresectable Gastric Adenocarcinoma: The TCOG 3211 Clinical Trial
por: Chen, Ming-Huang, et al.
Publicado: (2016)

Relapsed urachal carcinoma responding to first‐line chemotherapy with capecitabine‐oxaliplatin plus bevacizumab
por: Hatano, Akihiko, et al.
Publicado: (2023)

A Phase II Clinical Trial on the Combination Therapy of PHY906 Plus Capecitabine in Hepatocellular Carcinoma
por: Changou, Chun A., et al.
Publicado: (2020)

S-1 plus oxaliplatin versus capecitabine plus oxaliplatin for the first-line treatment of patients with metastatic colorectal cancer: updated results from a phase 3 trial
por: Kim, Seung Tae, et al.
Publicado: (2014)

Bevacizumab plus capecitabine as later-line treatment for patients with metastatic colorectal cancer refractory to irinotecan, oxaliplatin, and fluoropyrimidines
por: Bang, Yeong Hak, et al.
Publicado: (2021)

Phase I trial of capecitabine plus everolimus (RAD001) in patients with previously treated metastatic gastric cancer
por: Lim, Taekyu, et al.
Publicado: (2011)

Efficacy and Safety of Docetaxel Plus Oxaliplatin and Capecitabine in the First Line Treatment of Advanced Gastric Adenocarcinoma
por: Liu, Ying, et al.
Publicado: (2013)

Capecitabine plus oxaliplatin in the treatment of metastatic colorectal cancer at Tygerberg Hospital: a retrospective study
por: Kibudde, Solomon, et al.
Publicado: (2022)

Prostate-specific antigen reduction after capecitabine plus oxaliplatin chemotherapy: A case report
por: Zou, Qian, et al.
Publicado: (2023)

Multicenter phase II study of capecitabine plus oxaliplatin in older patients with advanced gastric cancer: the Tokyo Cooperative Oncology Group (TCOG) GI-1601 study
por: Kawabata, Ryohei, et al.
Publicado: (2023)

Prospective clinical study of capecitabine plus oxaliplatin concurrent chemoradiotherapy after radical resection of rectal cancer
por: Chen, Wanghua, et al.
Publicado: (2018)

Comparison of the Efficacy of S-1 Plus Oxaliplatin or Capecitabine Plus Oxaliplatin for Six and Eight Chemotherapy Cycles as Adjuvant Chemotherapy in Patients With Stage II-III Gastric Cancer After D2 Resection
por: Yu, Yuanyuan, et al.
Publicado: (2021)

Weekly Paclitaxel plus Capecitabine versus Docetaxel Every 3 Weeks plus Capecitabine in Metastatic Breast Cancer
por: Wist, E. A., et al.
Publicado: (2012)

Comparison of S‐1 plus oxaliplatin (SOX) and capecitabine plus oxaliplatin (XELOX) as adjuvant chemotherapies for stage II and III gastric cancer after D2 resection: A single‐center retrospective study
por: Jiang, Zhichao, et al.
Publicado: (2020)

Randomised phase II trial of trifluridine/tipiracil (FTD/TPI) plus ramucirumab (RAM) versus trifluridine/tipiracil for previously treated patients with advanced gastric or esophagogastric junction adenocarcinoma (RETRIEVE study, WJOG15822G)
por: Takahashi, Naoki, et al.
Publicado: (2023)

Two doses of NGR-hTNF in combination with capecitabine plus oxaliplatin in colorectal cancer patients failing standard therapies
por: Mammoliti, S., et al.
Publicado: (2011)

Immune checkpoint inhibitors plus capecitabine and oxaliplatin in unresectable or advanced biliary tract cancer patients: A retrospective study
por: Zhao, Jie, et al.
Publicado: (2022)

The efficacy and safety of apatinib plus capecitabine in platinum-refractory metastatic and/or recurrent nasopharyngeal carcinoma: a prospective, phase II trial
por: Tang, Lin-Quan, et al.
Publicado: (2023)

Phase II Trial Using a Combination of Oxaliplatin, Capecitabine, and Celecoxib with Concurrent Radiation for Newly Diagnosed Resectable Rectal Cancer
por: Araujo‐Mino, Emilio P., et al.
Publicado: (2017)

Economic evaluation of third-line neratinib plus capecitabine versus lapatinib plus capecitabine with HER2+ metastatic breast cancer
por: Ren, Lanqi, et al.
Publicado: (2023)

A phase II study of capecitabine plus 3-weekly oxaliplatin as first-line therapy for patients with advanced gastric cancer
por: Park, Y H, et al.
Publicado: (2006)

XELOX (capecitabine plus oxaliplatin) as first-line treatment for elderly patients over 70 years of age with advanced colorectal cancer
por: Feliu, J, et al.
Publicado: (2006)

Multicentre phase II trial of capecitabine plus oxaliplatin (XELOX) in patients with advanced hepatocellular carcinoma: FFCD 03-03 trial
por: Boige, V, et al.
Publicado: (2007)

Factors Influencing Clinicians' Choice of Adjuvant S-1 versus Capecitabine plus Oxaliplatin after Curative Gastrectomy in Patients with Gastric Cancer
por: Lee, Ha Yeon, et al.
Publicado: (2016)

Prospective phase II trial of pazopanib plus CapeOX (capecitabine and oxaliplatin) in previously untreated patients with advanced gastric cancer
por: Kim, Seung Tae, et al.
Publicado: (2016)

A Modified Epirubicin and Oxaliplatin Plus Capecitabine (EOX) Regimen as a Second- Line Therapy in Patients with Advanced Gastric Cancer
por: Bozkaya, Yakup, et al.
Publicado: (2018)

Adjuvant capecitabine plus oxaliplatin after D2 gastrectomy in Japanese patients with gastric cancer: a phase II study
por: Fuse, Nozomu, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_ik3b7f8d7995j3frkg870g09mp